Stone Pharmaceuticals Innovation: the application for listing Envirotuzumab Injection by its holding subsidiary has been accepted.

Stone Pharmaceutical Innovation Announcement: Huiheng Bio-Pharmaceutical Co., Ltd., a holding subsidiary of Stone Pharmaceutical Group, recently received the "Acceptance Letter" issued by the National Medical Products Administration for the approval of the listing application for Envida Kishuzumab Monoclonal Antibody Injection. Envida Kishuzumab Monoclonal Antibody Injection is a targeted HER2 antibody drug conjugate intended for the treatment of unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.